Abstract
111P Interim biomarker analysis of a phase Ib/II study of anti-TIGIT etigilimab (MPH313) and nivolumab in subjects with select locally advanced or metastatic solid tumors (ACTIVATE)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have